Cardiovascular Disease Archives - Infectious Disease Advisor

Significant QT Prolongation Associated With Chloroquine/Hydroxychloroquine Treatment for COVID-19

By

Dibash Das, PhD

June 12, 2020

The treatment of patients with COVID-19 with chloroquine or hydroxychloroquine may result in significant QT prolongation.

COVID19

Handheld Echocardiogram Adequate to Screen COVID-19-Related Cardiac Complications

By

Dibash Das, PhD

June 2, 2020

Limited tablet cardiac ultrasound was found to represent an effective alternative to standard platform imaging for the screening of COVID-19-related cardiac conditions.

A blood sample is taken for a lipid panel.

COVID19

Hypolipidemia Associated With COVID-19, Worsens With Disease Severity

By

Dibash Das, PhD

June 1, 2020

Hypolipidemia was found to be associated with COVID-19, and to worsen with disease severity.

COVID19

Joint Statement Issued on Reducing Arrhythmia Risk With COVID-19 Repurposed Drugs

By

Diana Ernst, RPh

April 14, 2020

Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.

Approximately 50% of people with HIV have dyslipidemia.3 Common lipid disorders in treated or untreated patients are elevated triglyceride levels and decreased levels of total, high-density lipoprotein, and low-density lipoprotein cholesterol.3,8 Studies consistently associate ART with lipid changes, which may be a direct effect of ART or may result from viral suppression.3,6,8,9 Typical onset of dyslipidemia is within 3 months of starting ART.8 The PIs most likely to induce dyslipidemia are lopinavir, ritonavir, fosamprenavir, and tipranavir; whereas, atazanavir and darunavir are less likely to cause dyslipidemia.3 The non-NRTI efavirenz poses a greater risk for dyslipidemia than the non-NRTIs rilpivirine, etravirine, and nevirapine.3 Older NRTIs affected lipid levels adversely but are rarely used, and the newer NRTIs tenofovir and abacavir may even improve lipid levels.3 Raltegravir and dolutegravir are integrase strand transfer inhibitors, which tend to be lipid neutral and are preferred first-line agents.3

HIV/AIDS

Higher Rate of Dyslipidemia Among Women Living With HIV

By

Bradley van Paridon

April 9, 2020

Despite relatively young ages, a significantly greater percentage of women living with HIV had dyslipidemia than did controls.

HIV/AIDS

Mood Disorders With HIV Increase Risk for Noncommunicable Disease

By

Zahra Masoud

March 31, 2020

Focused prevention and treatment of noncommunicable diseases may reduce the burden of multimorbidity in people living with HIV who have mood disorders and multimorbidity.

CROI 2020

Cardiac Events Significantly Higher With TAF vs TDF Treatment for HIV

By

Infectious Disease Advisor Contributing Writer

March 25, 2020

The occurrence of cardiac events in a cohort of patients with HIV was significantly higher in patients treated with tenofovir-alafenamide.

CROI 2020

Increased Cardiovascular Disease Risk Among Youth Living With HIV

By

Bradley van Paridon

March 25, 2020

Research results revealed increased risks for cardiovascular disease and insulin resistance among young individuals with HIV.

Hepatitis

HCV Cure Shows No Effect on Markers of Preclinical Atherosclerosis in HIV/HCV Coinfection

By

Sweta Gupta

March 19, 2020 11:30 am

Among patients coinfected with HIV/HCV, there were no medium-term beneficial effects of sustained virologic response on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.

GI Illness

Multiple Sclerosis Susceptibility Associated With Certain Gut Bacteria

By

Infectious Disease Advisor Contributing Writer

March 4, 2020

A network of gut bacteria species may be associated with host genetic factors that increase susceptibility to multiple sclerosis.